239 related articles for article (PubMed ID: 34234609)
1. Profile and Management of Toxicity of Selinexor and Belantamab Mafodotin for the Treatment of Triple Class Refractory Multiple Myeloma.
Neupane K; Wahab A; Masood A; Faraz T; Bahram S; Ehsan H; Hannan A; Anwer F
J Blood Med; 2021; 12():529-550. PubMed ID: 34234609
[TBL] [Abstract][Full Text] [Related]
2. DREAMM-2: Indirect Comparisons of Belantamab Mafodotin vs. Selinexor + Dexamethasone and Standard of Care Treatments in Relapsed/Refractory Multiple Myeloma.
Prawitz T; Popat R; Suvannasankha A; Sarri G; Hughes R; Wang F; Hogea C; Ferrante SA; Gorsh B; Willson J; Kapetanakis V
Adv Ther; 2021 Nov; 38(11):5501-5518. PubMed ID: 34561812
[TBL] [Abstract][Full Text] [Related]
3. The role of belantamab mafodotin for patients with relapsed and/or refractory multiple myeloma.
Becnel MR; Lee HC
Ther Adv Hematol; 2020; 11():2040620720979813. PubMed ID: 33403093
[TBL] [Abstract][Full Text] [Related]
4. Ocular Toxicity of Belantamab Mafodotin, an Oncological Perspective of Management in Relapsed and Refractory Multiple Myeloma.
Wahab A; Rafae A; Mushtaq K; Masood A; Ehsan H; Khakwani M; Khan A
Front Oncol; 2021; 11():678634. PubMed ID: 34046363
[TBL] [Abstract][Full Text] [Related]
5. Novel Approaches to Treating Relapsed and Refractory Multiple Myeloma with a Focus on Recent Approvals of Belantamab Mafodotin and Selinexor.
Joseph NS; Tai YT; Anderson KC; Lonial S
Clin Pharmacol; 2021; 13():169-180. PubMed ID: 34434061
[TBL] [Abstract][Full Text] [Related]
6. Belantamab mafodotin for the treatment of relapsed/refractory multiple myeloma in heavily pretreated patients: a US cost-effectiveness analysis.
Nikolaou A; Ambavane A; Shah A; Ma W; Tosh J; Kapetanakis V; Willson J; Wang F; Hogea C; Gorsh B; Gutierrez B; Sapra S; Suvannasankha A; Samyshkin Y
Expert Rev Hematol; 2021 Dec; 14(12):1137-1145. PubMed ID: 34465265
[TBL] [Abstract][Full Text] [Related]
7. The Role of Belantamab Mafodotin, Selinexor, and Melflufen in Multiple Myeloma.
McCurdy A; Visram A
Curr Hematol Malig Rep; 2022 Dec; 17(6):306-318. PubMed ID: 36417082
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of belantamab mafodotin with pembrolizumab in patients with relapsed or refractory multiple myeloma.
Suvannasankha A; Bahlis N; Trudel S; Weisel K; Koenecke C; Oriol A; Voorhees PM; Alonso AA; Callander NS; Mateos MV; Reddy N; Hakim S; LaMacchia J; Patel N; Williams D; Jewell RC; Zhou X; Gupta I; Opalinska J; Nooka AK
Cancer; 2024 Apr; ():. PubMed ID: 38630908
[TBL] [Abstract][Full Text] [Related]
9. Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma: Results of the Compassionate Use or the Expanded Access Program in Spain.
de la Rubia J; Alonso R; Clavero ME; Askari E; García A; Antón C; Fernández M; Escalante F; García A; Rios-Tamayo R; Conesa V; Bermúdez MA; Merchán B; Velasco AE; Blanchard MJ; Sampol A; Gainza E; Hernández PM; Alegre A
Cancers (Basel); 2023 May; 15(11):. PubMed ID: 37296925
[TBL] [Abstract][Full Text] [Related]
10. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study.
Lonial S; Lee HC; Badros A; Trudel S; Nooka AK; Chari A; Abdallah AO; Callander N; Lendvai N; Sborov D; Suvannasankha A; Weisel K; Karlin L; Libby E; Arnulf B; Facon T; Hulin C; Kortüm KM; Rodríguez-Otero P; Usmani SZ; Hari P; Baz R; Quach H; Moreau P; Voorhees PM; Gupta I; Hoos A; Zhi E; Baron J; Piontek T; Lewis E; Jewell RC; Dettman EJ; Popat R; Esposti SD; Opalinska J; Richardson P; Cohen AD
Lancet Oncol; 2020 Feb; 21(2):207-221. PubMed ID: 31859245
[TBL] [Abstract][Full Text] [Related]
11. Belantamab Mafodotin for the Treatment of Multiple Myeloma: An Overview of the Clinical Efficacy and Safety.
Offidani M; Corvatta L; Morè S; Olivieri A
Drug Des Devel Ther; 2021; 15():2401-2415. PubMed ID: 34103900
[TBL] [Abstract][Full Text] [Related]
12. EMA Review of Belantamab Mafodotin (Blenrep) for the Treatment of Adult Patients with Relapsed/Refractory Multiple Myeloma.
Tzogani K; Penttilä K; Lähteenvuo J; Lapveteläinen T; Lopez Anglada L; Prieto C; Garcia-Ochoa B; Enzmann H; Gisselbrecht C; Delgado J; Pignatti F
Oncologist; 2021 Jan; 26(1):70-76. PubMed ID: 33179377
[TBL] [Abstract][Full Text] [Related]
13. Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody-Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study.
Farooq AV; Degli Esposti S; Popat R; Thulasi P; Lonial S; Nooka AK; Jakubowiak A; Sborov D; Zaugg BE; Badros AZ; Jeng BH; Callander NS; Opalinska J; Baron J; Piontek T; Byrne J; Gupta I; Colby K
Ophthalmol Ther; 2020 Dec; 9(4):889-911. PubMed ID: 32712806
[TBL] [Abstract][Full Text] [Related]
14. Budget Impact of Belantamab Mafodotin (Belamaf) Adoption in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma in the United States.
Shah A; Tosh JC; Ambavane A; Nikolaou A; Hogea C; Samyshkin Y; Gorsh B; Maiese EM; Wang F
Clinicoecon Outcomes Res; 2021; 13():789-800. PubMed ID: 34531667
[TBL] [Abstract][Full Text] [Related]
15. Single-agent belantamab mafodotin in patients with relapsed/refractory multiple myeloma: Final analysis of the DREAMM-2 trial.
Nooka AK; Cohen AD; Lee HC; Badros A; Suvannasankha A; Callander N; Abdallah AO; Trudel S; Chari A; Libby EN; Chaudhry M; Hultcrantz M; Kortüm KM; Popat R; Sborov D; Hakim S; Lewis E; Gorsh B; Bhushan B; McKeown A; Gupta I; Opalinska J; Richardson PG; Lonial S
Cancer; 2023 Dec; 129(23):3746-3760. PubMed ID: 37622738
[TBL] [Abstract][Full Text] [Related]
16. Real-World Outcomes of Belantamab Mafodotin for Relapsed/Refractory Multiple Myeloma (RRMM): Preliminary Results of a Spanish Expanded Access Program (EAP).
Alegre A; Benzo G; Alonso R; Martínez-López J; Jimenez-Ubieto A; Cuéllar C; Askari E; Prieto E; Aláez C; Aguado B; Velasco A; Krsnik I; Bocanegra A; Llorente L; Muñoz-Linares C; Morales A; Giménez E; Iglesias R; Martínez-Chamorro C; Alonso A; Jiménez-Montes C; Blanchard MJ;
Oncol Ther; 2023 Mar; 11(1):83-96. PubMed ID: 36509945
[TBL] [Abstract][Full Text] [Related]
17. Belantamab Mafodotin to Treat Multiple Myeloma: A Comprehensive Review of Disease, Drug Efficacy and Side Effects.
Lassiter G; Bergeron C; Guedry R; Cucarola J; Kaye AM; Cornett EM; Kaye AD; Varrassi G; Viswanath O; Urits I
Curr Oncol; 2021 Jan; 28(1):640-660. PubMed ID: 33494319
[TBL] [Abstract][Full Text] [Related]
18. Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM).
Lonial S; Nooka AK; Thulasi P; Badros AZ; Jeng BH; Callander NS; Potter HA; Sborov D; Zaugg BE; Popat R; Degli Esposti S; Byrne J; Opalinska J; Baron J; Piontek T; Gupta I; Dana R; Farooq AV; Colby K; Jakubowiak A
Blood Cancer J; 2021 May; 11(5):103. PubMed ID: 34039952
[TBL] [Abstract][Full Text] [Related]
19. Real-world experience with belantamab mafodotin therapy for relapsed/refractory multiple myeloma: A multicentre retrospective study.
Shragai T; Magen H; Lavi N; Gatt M; Trestman S; Zektser M; Ganzel C; Jarchowsky O; Berger T; Tadmor T; Leiba M; Hertzog-Tzarfaty K; Horowitz N; Shapira M; Varssano D; Berger Y; Frenkel S; Krauthammer M; Avivi I; Luttwak E; Cohen YC;
Br J Haematol; 2023 Jan; 200(1):45-53. PubMed ID: 36205375
[TBL] [Abstract][Full Text] [Related]
20. Longer term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-month follow-up from the pivotal DREAMM-2 study.
Lonial S; Lee HC; Badros A; Trudel S; Nooka AK; Chari A; Abdallah AO; Callander N; Sborov D; Suvannasankha A; Weisel K; Voorhees PM; Womersley L; Baron J; Piontek T; Lewis E; Opalinska J; Gupta I; Cohen AD
Cancer; 2021 Nov; 127(22):4198-4212. PubMed ID: 34314018
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
